Kosmidis, Chris http://orcid.org/0000-0003-0662-1265
Mackenzie, Anna
Harris, Chris
Hashad, Rola
Lynch, Fiona
Denning, David W.
Funding for this research was provided by:
University of Manchester
Article History
Received: 28 February 2020
Accepted: 20 July 2020
First Online: 21 August 2020
Compliance with ethical standards
:
: Chris Kosmidis, Anna Mackenzie, Rola Hashad, Chris Harris and Fiona Lynch report no conflicts of interest. DW Denning and family hold Founder shares in F2G Ltd., a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Scynexis, Pulmatrix, Zambon, iCo Therapeutics, Roivant, Biosergen and Fujifilm. In the last 3 years, he has been paid for talks on behalf of Dynamiker, Hikma, Gilead, Merck, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group and the British Society for Medical Mycology Standards of Care committee.
: This study was a retrospective service evaluation and ethical approval was not required, according to UK Health Research Authority guidelines. The study was registered with the audit department of Manchester University NHS Foundation Trust (Audit No. 8056).
: Informed consent was not required as all data is anonymised.